Skip to main content
Erschienen in: Advances in Therapy 4/2017

02.03.2017 | Review

Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies

verfasst von: Ferdinando Fusco, Massimiliano Creta, Vittorio Imperatore, Nicola Longo, Ciro Imbimbo, Herbert Lepor, Vincenzo Mirone

Erschienen in: Advances in Therapy | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Benign prostatic obstruction (BPO) contributes to the genesis of lower urinary tract symptoms as well as to pathologic remodeling of the lower and upper urinary tract in patients with benign prostate enlargement. Urodynamic studies demonstrate that both medical therapy with alpha-blockers (ABs) and endoscopic surgical procedures provide BPO relief. However, the magnitude of improvement is higher after surgery. Among ABs, silodosin is associated with the highest improvement of bladder outlet obstruction index (BOOI). A complex relationship exists between BOOI improvement and variations of both maximum urinary flow (Q max) and detrusor pressure. When the reduction of BOOI is small, the improvement of Q max is clinically irrelevant and the BOOI is mainly influenced by a decrease of detrusor pressure. In contrast, when the magnitude of BOOI reduction is robust, a meaningful improvement of both detrusor pressure and urinary flow is evident. When clustering ABs according to their receptor pharmacologic selectivity and urodynamic efficacy, three subgroups can be identified,with silodosin being the only member of a subgroup characterized by the highest levels of BOOI improvement and α-1A/α-1B receptor affinity ratio.
Literatur
1.
Zurück zum Zitat Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl 4):S3–9.PubMedPubMedCentral Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl 4):S3–9.PubMedPubMedCentral
2.
Zurück zum Zitat Levin RM, Longhurst PA, Monson FC, Kato K, Wein AJ. Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl. 1990;3:9–26.CrossRefPubMed Levin RM, Longhurst PA, Monson FC, Kato K, Wein AJ. Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl. 1990;3:9–26.CrossRefPubMed
3.
Zurück zum Zitat Macey MR, Raynor MC. Medical and surgical treatment modalities for lower urinary tract symptoms in the male patient secondary to benign prostatic hyperplasia: a review. Semin Intervent Radiol. 2016;33(3):217–23. doi:10.1055/s-0036-1586142.CrossRefPubMed Macey MR, Raynor MC. Medical and surgical treatment modalities for lower urinary tract symptoms in the male patient secondary to benign prostatic hyperplasia: a review. Semin Intervent Radiol. 2016;33(3):217–23. doi:10.​1055/​s-0036-1586142.CrossRefPubMed
4.
Zurück zum Zitat Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(Suppl 9):S3–10. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(Suppl 9):S3–10.
5.
Zurück zum Zitat Fusco F, Palmieri A, Ficarra V, et al. α1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69(6):1091–101.CrossRefPubMed Fusco F, Palmieri A, Ficarra V, et al. α1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69(6):1091–101.CrossRefPubMed
6.
Zurück zum Zitat Oelke M, Bachmann A, Descazeaud A, et al. European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptomsincluding benign prostatic obstruction. Eur Urol. 2013;64(1):118–40.CrossRefPubMed Oelke M, Bachmann A, Descazeaud A, et al. European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptomsincluding benign prostatic obstruction. Eur Urol. 2013;64(1):118–40.CrossRefPubMed
7.
Zurück zum Zitat Nitti VW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol. 2005;7(Suppl 6):S14–21.PubMedPubMedCentral Nitti VW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol. 2005;7(Suppl 6):S14–21.PubMedPubMedCentral
8.
Zurück zum Zitat Jung YG, Kang MS, Heo J. Clustering performance comparison using K-means and expectation maximization algorithms. Biotechnol Biotechnol Equip. 2014;28(sup1):S44–8.CrossRefPubMedPubMedCentral Jung YG, Kang MS, Heo J. Clustering performance comparison using K-means and expectation maximization algorithms. Biotechnol Biotechnol Equip. 2014;28(sup1):S44–8.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Akiyama K, Hora M, Tatemichi S, et al. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. Pharmacol Exp Ther. 1999;291(1):81–91. Akiyama K, Hora M, Tatemichi S, et al. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. Pharmacol Exp Ther. 1999;291(1):81–91.
10.
Zurück zum Zitat Tatemichi S, Kobayashi K, Yokoi R, et al. Comparison of the effects of four α1-adrenoceptor antagonists on ejaculatory function in rats. Urology. 2012;80(2):486.e9.CrossRef Tatemichi S, Kobayashi K, Yokoi R, et al. Comparison of the effects of four α1-adrenoceptor antagonists on ejaculatory function in rats. Urology. 2012;80(2):486.e9.CrossRef
11.
Zurück zum Zitat Kenny BA, Miller AM, Williamson IJ, O’Connell J, Chalmers DH, Naylor AM. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996;118(4):871–8.CrossRefPubMedPubMedCentral Kenny BA, Miller AM, Williamson IJ, O’Connell J, Chalmers DH, Naylor AM. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996;118(4):871–8.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Lepor H. Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease. Rev Urol. 2009;11(Suppl 1):S9–13.PubMedPubMedCentral Lepor H. Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease. Rev Urol. 2009;11(Suppl 1):S9–13.PubMedPubMedCentral
13.
Zurück zum Zitat Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997;80:587–96.CrossRefPubMed Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997;80:587–96.CrossRefPubMed
14.
Zurück zum Zitat Yamanishi T, Yasuda K, Kamai T, et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol. 2004;11:501–9.CrossRefPubMed Yamanishi T, Yasuda K, Kamai T, et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol. 2004;11:501–9.CrossRefPubMed
15.
Zurück zum Zitat Rossi C, Kortmann BB, Sonke GS, et al. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol. 2001;165:38–41.CrossRefPubMed Rossi C, Kortmann BB, Sonke GS, et al. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol. 2001;165:38–41.CrossRefPubMed
16.
Zurück zum Zitat Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Urology. 1997;49:197–205.CrossRefPubMed Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Urology. 1997;49:197–205.CrossRefPubMed
17.
Zurück zum Zitat Witjes WP, Rosier FW, de Wildt MJ, van Iersel MP, Debruyne FM, de La Rosette JJ. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. J Urol. 1996;155:1317–23.CrossRefPubMed Witjes WP, Rosier FW, de Wildt MJ, van Iersel MP, Debruyne FM, de La Rosette JJ. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. J Urol. 1996;155:1317–23.CrossRefPubMed
18.
Zurück zum Zitat Arnold EP. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand. BJU Int. 2001;87:24–30.CrossRefPubMed Arnold EP. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand. BJU Int. 2001;87:24–30.CrossRefPubMed
19.
Zurück zum Zitat Gerber GS, Kim JH, Contreras BA, Steinberg GD, Rukstalis DB. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology. 1996;47:840–4.CrossRefPubMed Gerber GS, Kim JH, Contreras BA, Steinberg GD, Rukstalis DB. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology. 1996;47:840–4.CrossRefPubMed
20.
Zurück zum Zitat Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010;29:558–62.PubMed Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010;29:558–62.PubMed
21.
Zurück zum Zitat Tanaka Y, Masumori N, Itoh N, et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol. 2002;167:2492–5.CrossRefPubMed Tanaka Y, Masumori N, Itoh N, et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol. 2002;167:2492–5.CrossRefPubMed
22.
Zurück zum Zitat Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. J Urol. 2009;182:2831–5.CrossRefPubMed Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. J Urol. 2009;182:2831–5.CrossRefPubMed
23.
Zurück zum Zitat Martorana G, Giberti C, Di Silverio F, et al. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol. 1997;32:47–53.PubMed Martorana G, Giberti C, Di Silverio F, et al. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol. 1997;32:47–53.PubMed
24.
Zurück zum Zitat Ozbey I, Aksoy Y, Polat O, Biçgi O, Demirel A, Okyar G. Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. Int Urol Nephrol. 1999;31:471–9.CrossRefPubMed Ozbey I, Aksoy Y, Polat O, Biçgi O, Demirel A, Okyar G. Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. Int Urol Nephrol. 1999;31:471–9.CrossRefPubMed
25.
Zurück zum Zitat De Nunzio C, Franco G, Iori F, Leonardo C, Minardi V, Laurenti C. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR. Urol Int. 2003;71:31–6.CrossRefPubMed De Nunzio C, Franco G, Iori F, Leonardo C, Minardi V, Laurenti C. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR. Urol Int. 2003;71:31–6.CrossRefPubMed
26.
Zurück zum Zitat Regadas RP, Reges R, Cerqueira JB, et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol. 2013;45:39–43.CrossRefPubMed Regadas RP, Reges R, Cerqueira JB, et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol. 2013;45:39–43.CrossRefPubMed
27.
Zurück zum Zitat Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006;97:747–51.CrossRefPubMed Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006;97:747–51.CrossRefPubMed
28.
Zurück zum Zitat Gleason DM, Bottaccini MR. Effect of terazosin on urine storage and voiding in the aging male with prostatism. Neurourol Urodyn. 1994;13:1–12.CrossRefPubMed Gleason DM, Bottaccini MR. Effect of terazosin on urine storage and voiding in the aging male with prostatism. Neurourol Urodyn. 1994;13:1–12.CrossRefPubMed
29.
Zurück zum Zitat Sriplakich S, Promwatcharanon K. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction. J Med Assoc Thail. 2007;90:2326–31. Sriplakich S, Promwatcharanon K. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction. J Med Assoc Thail. 2007;90:2326–31.
30.
Zurück zum Zitat Wilson LC, Gilling PJ, Williams A, et al. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50(3):569–73.CrossRefPubMed Wilson LC, Gilling PJ, Williams A, et al. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50(3):569–73.CrossRefPubMed
31.
Zurück zum Zitat Montorsi F, Naspro R, Salonia A, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172(5 Pt 1):1926–9.CrossRefPubMed Montorsi F, Naspro R, Salonia A, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172(5 Pt 1):1926–9.CrossRefPubMed
32.
Zurück zum Zitat Han DH, Choo SH, Chung JW, Hong JH, Lee SW. Can 80 W KTP laser vaporization effectively relieve the obstruction in benign prostatic hyperplasia? A nonrandomized trial. World J Mens Health. 2012;30(3):160–5.CrossRefPubMedPubMedCentral Han DH, Choo SH, Chung JW, Hong JH, Lee SW. Can 80 W KTP laser vaporization effectively relieve the obstruction in benign prostatic hyperplasia? A nonrandomized trial. World J Mens Health. 2012;30(3):160–5.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003;170(4 Pt 1):1270–4.CrossRefPubMed Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003;170(4 Pt 1):1270–4.CrossRefPubMed
34.
Zurück zum Zitat Tuhkanen K, Heino A, Alaopas M. Hybrid laser treatment compared with transurethral resection of the prostate for symptomatic bladder outlet obstruction caused by a large benign prostate: a prospective, randomized trial with a 6-month follow-up. BJU Int. 1999;84(7):805–9.CrossRefPubMed Tuhkanen K, Heino A, Alaopas M. Hybrid laser treatment compared with transurethral resection of the prostate for symptomatic bladder outlet obstruction caused by a large benign prostate: a prospective, randomized trial with a 6-month follow-up. BJU Int. 1999;84(7):805–9.CrossRefPubMed
35.
Zurück zum Zitat Tuhkanen K, Heino A, Ala-Opas M. Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml. Six-month follow-up with complex urodynamic assessment. Scand J Urol Nephrol. 1999;33(1):31–4.CrossRefPubMed Tuhkanen K, Heino A, Ala-Opas M. Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml. Six-month follow-up with complex urodynamic assessment. Scand J Urol Nephrol. 1999;33(1):31–4.CrossRefPubMed
36.
Zurück zum Zitat Mostafid AH, Harrison NW, Thomas PJ, Fletcher MS. A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. Br J Urol. 1997;80(1):116–22.CrossRefPubMed Mostafid AH, Harrison NW, Thomas PJ, Fletcher MS. A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. Br J Urol. 1997;80(1):116–22.CrossRefPubMed
37.
Zurück zum Zitat Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. J Urol. 2005;174(5):1887–91.CrossRefPubMed Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. J Urol. 2005;174(5):1887–91.CrossRefPubMed
38.
Zurück zum Zitat Pereira-Correia JA, de Moraes Sousa KD, Santos JB, et al. GreenLight HPS™ 120-W laser vaporization vs transurethral resection of the prostate (<60 mL): a 2-year randomized double-blind prospective urodynamic investigation. BJU Int. 2012;110(8):1184–9.CrossRefPubMed Pereira-Correia JA, de Moraes Sousa KD, Santos JB, et al. GreenLight HPS™ 120-W laser vaporization vs transurethral resection of the prostate (<60 mL): a 2-year randomized double-blind prospective urodynamic investigation. BJU Int. 2012;110(8):1184–9.CrossRefPubMed
39.
Zurück zum Zitat Wagrell L, Schelin S, Nordling J, et al. Feedback microwave thermotherapy versus TURP for clinical BPH—a randomized controlled multicenter study. Urology. 2002;60(2):292–9.CrossRefPubMed Wagrell L, Schelin S, Nordling J, et al. Feedback microwave thermotherapy versus TURP for clinical BPH—a randomized controlled multicenter study. Urology. 2002;60(2):292–9.CrossRefPubMed
40.
Zurück zum Zitat Aho TF, Gilling PJ, Kennett KM, Westenberg AM, Fraundorfer MR, Frampton CM. Holmium laser bladder neck incision versus holmium enucleation of the prostate as outpatient procedures for prostates less than 40 grams: a randomized trial. J Urol. 2005;174(1):210–4.CrossRefPubMed Aho TF, Gilling PJ, Kennett KM, Westenberg AM, Fraundorfer MR, Frampton CM. Holmium laser bladder neck incision versus holmium enucleation of the prostate as outpatient procedures for prostates less than 40 grams: a randomized trial. J Urol. 2005;174(1):210–4.CrossRefPubMed
41.
Zurück zum Zitat Wille S, Al Mahmid M, Schumacher P, et al. Urodynamic effect of 80 watt photoselective laser vaporization of the prostate. Scand J Urol. 2013;47(5):378–83.CrossRefPubMed Wille S, Al Mahmid M, Schumacher P, et al. Urodynamic effect of 80 watt photoselective laser vaporization of the prostate. Scand J Urol. 2013;47(5):378–83.CrossRefPubMed
42.
Zurück zum Zitat Hamann MF, Naumann CM, Seif C, van der Horst C, Jünemann KP, Braun PM. Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up. Eur Urol. 2008;54(4):902–7.CrossRefPubMed Hamann MF, Naumann CM, Seif C, van der Horst C, Jünemann KP, Braun PM. Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up. Eur Urol. 2008;54(4):902–7.CrossRefPubMed
43.
Zurück zum Zitat Burney TL, Desautel MG, Badlani GH. Evaluation of transurethral vaporization of prostate with pressure-flow analysis and other clinical measures. J Endourol. 1996;10(5):469–72.CrossRefPubMed Burney TL, Desautel MG, Badlani GH. Evaluation of transurethral vaporization of prostate with pressure-flow analysis and other clinical measures. J Endourol. 1996;10(5):469–72.CrossRefPubMed
44.
Zurück zum Zitat Okada T, Terai A, Terachi T, Okada Y, Yoshida O. Transurethral electro-vaporization of the prostate: preliminary clinical results with pressure-flow analysis. Int J Urol. 1998;5(1):55–9 discussion 59–60.CrossRefPubMed Okada T, Terai A, Terachi T, Okada Y, Yoshida O. Transurethral electro-vaporization of the prostate: preliminary clinical results with pressure-flow analysis. Int J Urol. 1998;5(1):55–9 discussion 59–60.CrossRefPubMed
45.
Zurück zum Zitat Desautel MG, Burney TL, Diaz PA, Austria A, Badlani GH. Outcome of vaportrode transurethral vaporization of the prostate using pressure-flow urodynamic criteria. Urology. 1998;51(6):1013–7.CrossRefPubMed Desautel MG, Burney TL, Diaz PA, Austria A, Badlani GH. Outcome of vaportrode transurethral vaporization of the prostate using pressure-flow urodynamic criteria. Urology. 1998;51(6):1013–7.CrossRefPubMed
46.
Zurück zum Zitat Porru D, Scarpa RM, Campus G, Delisa A, Montisci I, Usai E. Transurethral electro-vaporization of the prostate in benign prostatic hyperplasia. Evaluation of results using different urodynamic parameters. Scand J Urol Nephrol. 1998;32(2):123–6.CrossRefPubMed Porru D, Scarpa RM, Campus G, Delisa A, Montisci I, Usai E. Transurethral electro-vaporization of the prostate in benign prostatic hyperplasia. Evaluation of results using different urodynamic parameters. Scand J Urol Nephrol. 1998;32(2):123–6.CrossRefPubMed
47.
Zurück zum Zitat Shingleton WB, Kolski J, Renfroe DL, Fowler JE Jr. Electrovaporization of the prostate versus laser ablation of the prostate in men with benign prostatic hypertrophy: a pressure-flow analysis. Urol Int. 1998;60(4):224–8.CrossRefPubMed Shingleton WB, Kolski J, Renfroe DL, Fowler JE Jr. Electrovaporization of the prostate versus laser ablation of the prostate in men with benign prostatic hypertrophy: a pressure-flow analysis. Urol Int. 1998;60(4):224–8.CrossRefPubMed
48.
Zurück zum Zitat Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology. 1997;49(6):847–50.CrossRefPubMed Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology. 1997;49(6):847–50.CrossRefPubMed
49.
Zurück zum Zitat Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol. 1997;158(5):1834–8.CrossRefPubMed Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol. 1997;158(5):1834–8.CrossRefPubMed
50.
Zurück zum Zitat Alivizatos G, Ferakis N, Mitropoulos D, Skolarikos A, Livadas K, Kastriotis I. Feedback microwave thermotherapy with the ProstaLund Compact Device for obstructive benign prostatic hyperplasia: 12-month response rates and complications. J Endourol. 2005;19(1):72–8.CrossRefPubMed Alivizatos G, Ferakis N, Mitropoulos D, Skolarikos A, Livadas K, Kastriotis I. Feedback microwave thermotherapy with the ProstaLund Compact Device for obstructive benign prostatic hyperplasia: 12-month response rates and complications. J Endourol. 2005;19(1):72–8.CrossRefPubMed
51.
Zurück zum Zitat Thalmann GN, Mattei A, Treuthardt C, Burkhard FC, Studer UE. Transurethral microwave therapy in 200 patients with a minimum followup of 2 years: urodynamic and clinical results. J Urol. 2002;167(6):2496–501.CrossRefPubMed Thalmann GN, Mattei A, Treuthardt C, Burkhard FC, Studer UE. Transurethral microwave therapy in 200 patients with a minimum followup of 2 years: urodynamic and clinical results. J Urol. 2002;167(6):2496–501.CrossRefPubMed
52.
Zurück zum Zitat Thalmann GN, Graber SF, Bitton A, Burkhard FC, Gruenig O, Studer UE. Transurethral thermotherapy for benign prostatic hyperplasia significantly decreases infravesical obstruction: results in 134 patients after 1 year. J Urol. 1999;162(2):387–93.CrossRefPubMed Thalmann GN, Graber SF, Bitton A, Burkhard FC, Gruenig O, Studer UE. Transurethral thermotherapy for benign prostatic hyperplasia significantly decreases infravesical obstruction: results in 134 patients after 1 year. J Urol. 1999;162(2):387–93.CrossRefPubMed
53.
Zurück zum Zitat Krogh J, Hansen F, Nordling J. Transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: results obtained with the Prostalund device. World J Urol. 1998;16(2):115–9.CrossRefPubMed Krogh J, Hansen F, Nordling J. Transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: results obtained with the Prostalund device. World J Urol. 1998;16(2):115–9.CrossRefPubMed
54.
Zurück zum Zitat Wagrell L, Schelin S, Bolmsjö M, Brudin L. Intraprostatic temperature monitoring during transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia. J Urol. 1998;159(5):1583–7.CrossRefPubMed Wagrell L, Schelin S, Bolmsjö M, Brudin L. Intraprostatic temperature monitoring during transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia. J Urol. 1998;159(5):1583–7.CrossRefPubMed
55.
Zurück zum Zitat Kojima M, Inui E, Ochiai A, et al. Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction. J Urol. 1997;158(1):89–93.CrossRefPubMed Kojima M, Inui E, Ochiai A, et al. Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction. J Urol. 1997;158(1):89–93.CrossRefPubMed
56.
Zurück zum Zitat Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol. 2007;51(1):57–66.CrossRefPubMed Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol. 2007;51(1):57–66.CrossRefPubMed
57.
Zurück zum Zitat Roehrborn CG, Cruz F, Fusco F. α1-Blockers in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: is silodosin different? Adv Ther. 2017;33(12):2110–21.CrossRefPubMed Roehrborn CG, Cruz F, Fusco F. α1-Blockers in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: is silodosin different? Adv Ther. 2017;33(12):2110–21.CrossRefPubMed
58.
Zurück zum Zitat Creta M, Bottone F, Sannino S, Maisto E, Franco M, Mangiapia F, La Rocca R, Imperatore V, Longo N, Vivaldi O, Fusco F. Effects of alpha 1-blockers on urodynamic parameters of bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: a review. Minerva Urol Nefrol. 2015. [Epub ahead of print]. Creta M, Bottone F, Sannino S, Maisto E, Franco M, Mangiapia F, La Rocca R, Imperatore V, Longo N, Vivaldi O, Fusco F. Effects of alpha 1-blockers on urodynamic parameters of bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: a review. Minerva Urol Nefrol. 2015. [Epub ahead of print].
59.
Zurück zum Zitat Imperatore V, Fusco F, Creta M, et al. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014;86(2):103–7.CrossRefPubMed Imperatore V, Fusco F, Creta M, et al. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014;86(2):103–7.CrossRefPubMed
60.
Zurück zum Zitat Lepor H, Shapiro E. Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol. 1984;132(6):1226–9.PubMed Lepor H, Shapiro E. Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol. 1984;132(6):1226–9.PubMed
61.
Zurück zum Zitat Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993;149(3):640–2.PubMed Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993;149(3):640–2.PubMed
62.
Zurück zum Zitat Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol. 1993;150(6):2002–6.PubMed Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol. 1993;150(6):2002–6.PubMed
63.
Zurück zum Zitat Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol. 1999;161(2):635–40.CrossRefPubMed Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol. 1999;161(2):635–40.CrossRefPubMed
64.
Zurück zum Zitat Forray C, Bard JA, Wetzel JM, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45(4):703–8.PubMed Forray C, Bard JA, Wetzel JM, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45(4):703–8.PubMed
Metadaten
Titel
Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies
verfasst von
Ferdinando Fusco
Massimiliano Creta
Vittorio Imperatore
Nicola Longo
Ciro Imbimbo
Herbert Lepor
Vincenzo Mirone
Publikationsdatum
02.03.2017
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 4/2017
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0504-0

Weitere Artikel der Ausgabe 4/2017

Advances in Therapy 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.